Effect of an Innovative Online Ayurveda Program on the Mental and Physical Health of Home-Based Adults
Feasibility Trial of an Innovative Online Ayurveda Program for Detox and Lifestyle: Effect on Mental and Physical Health in Home-Based Adults
1 other identifier
interventional
98
1 country
1
Brief Summary
The overall objective of this study is to evaluate the effects, feasibility, and safety of a comprehensive online Ayurveda whole-systems (WS) intervention that targets the underlying etiological factors influencing mental and physical health symptoms. The primary hypothesis is that home-based adults who participate in the Ayurveda Program for Detox and Lifestyle will experience a decrease in anxiety and depression symptoms over 4 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable anxiety
Started Mar 2021
Typical duration for not_applicable anxiety
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 25, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 25, 2022
CompletedFirst Submitted
Initial submission to the registry
August 9, 2024
CompletedFirst Posted
Study publicly available on registry
August 13, 2024
CompletedDecember 9, 2024
December 1, 2024
1.4 years
August 9, 2024
December 4, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Change in Anxiety Score
Assessed using the online standardized Patient Health Questionnaire for Somatic, Anxiety, and Depressive Symptoms (PHQ-SADS). The PHQ-SADS uses cut-off points of 5, 10, and 15 to represent mild, moderate, and severe symptoms, respectively. The assessment includes the Generalized Anxiety Disorder 7-item (GAD-7) scale, which measures the severity of anxiety. The GAD-7 uses cut-off points of 5, 10, and 15 for mild, moderate, and severe anxiety, respectively. The scale ranges from 0 to 21, with higher scores indicating greater anxiety levels.
Assessed at baseline and once a month for four months
Change in Depression Score
Assessed using the online standardized Patient Health Questionnaire for Somatic, Anxiety, and Depressive Symptoms (PHQ-SADS). The PHQ-SADS uses cut-off points of 5, 10, and 15 to represent mild, moderate, and severe symptoms, respectively. The assessment also includes the Patient Health Questionnaire-9 (PHQ-9) for depression, which uses cut-off points of 5, 10, 15, and 20 to represent mild, moderate, moderately severe, and severe depression, respectively. The PHQ-9 scale ranges from 0 to 27, with higher scores indicating greater severity of depression.
Assessed at baseline and once a month for four months
Secondary Outcomes (3)
Change in Somatic or Physical Symptoms Score Change in Somatic or Physical Symptoms Score
Assessed at baseline and once a month for four months
Change in Fatigue Score
Assessed at baseline and once a month for four months
Changes in Body Mass Index (BMI)
Assessed at baseline and once a month for four months
Study Arms (1)
Intervention Group
EXPERIMENTALThe Online Ayurveda Program for Detox and Lifestyle Intervention Group will be divided into three individual psychophysiological Dosha-specific treatment groups. Participants will be assigned to these groups based on their results from the Ayurveda Dosha Self-Assessment questionnaire.
Interventions
The program includes personalized herbal remedies, detoxification procedures, dietary guidelines, yoga exercises, and daily routine practices.
Eligibility Criteria
You may qualify if:
- Scored ≥ 5 on the GAD-7
- Scored ≥ 5 on the PHQ-9
- Scored ≥ 5 on the PHQ-15
- Age 18-80 years
- No other psychiatric disorders
- Not receiving specialized treatments for anxiety or depression, nor participating in another clinical trial
- Stable psychiatric medication regimen for more than two months
- No acute or severe medical conditions
- Individuals who are not pregnant or breastfeeding
- Provided informed consent
You may not qualify if:
- Scored \< 5 on the GAD-7
- Scored \< 5 on the PHQ-9
- Scored \< 5 on the PHQ-15
- Age under 18 or over 80 years
- Other psychiatric disorders (e.g., suicidal risk)
- Currently undergoing specialized treatments for anxiety and depression, or participating in another clinical trial
- Psychiatric medication regimen for less than 2 months
- Acute or severe medical condition (e.g., stroke, surgery)
- Individuals who are pregnant or breastfeeding
- Inability to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Center for Maharishi AyurVeda and Holistic Medicine
Geboltskirchen, 4682, Austria
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Viktoria Luhaste, PhD
Maharishi International University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator, Department of Physiology and Health
Study Record Dates
First Submitted
August 9, 2024
First Posted
August 13, 2024
Study Start
March 10, 2021
Primary Completion
July 25, 2022
Study Completion
July 25, 2022
Last Updated
December 9, 2024
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- IPD will be available six months after the study results are published in a peer-reviewed journal and will be accessible for up to three years after that.
- Access Criteria
- Researchers must submit a methodologically sound proposal for review by the data-sharing committee and the institutional review board of Maharishi International University, Fairfield, Iowa. The committee will approve access, and a data use agreement must be signed prior to data release.
The research data supporting this study's findings are not publicly accessible due to privacy and ethical constraints related to patient consent. However, anonymized data may be available from the authors upon request with permission from the institutional review board of Maharishi International University, Fairfield, Iowa.